Future perspectives and challenges for identification and recognition of clinically significant cancer biomarkers

The identification and detection of clinically meaningful cancer biomarkers are at the core of precision oncology development, with the potential to revolutionize cancer screening, diagnosis, prognosis, and targeted therapeutic approaches. The shifting paradigm of cancer biomarker discovery, including both new opportunities and old challenges preventing clinical translation, will be the subject of this chapter. Biomarkers such as genetic mutation, epigenetic alteration, protein expression profiling, and metabolomic fingerprints play a central role in stratifying cancer patients, predicting treatment efficacy, and monitoring disease progression. Advances in technologies at breakneck pace NGS, single-cell omics, proteomics, and artificial intelligence (AI)-driven analytics have significantly boosted the capacity to decode tumor heterogeneity, clonal evolution, and microenvironment interactions. Of particular interest, liquid biopsy platforms that focus on circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs are transforming non-invasive diagnostics with the potential for early detection and real-time monitoring of disease. Bringing candidate biomarkers to fully validated clinical tests, however, is an elusive goal. The current chapter critically assesses barriers like biological heterogeneity, lack of adequate assay standardization, sparse longitudinal validation, and variability in data interpretation across different platforms and populations. Tumor plasticity and pressure from therapy-induced dynamic alterations further cloud biomarker dependability, necessitating adaptive and integrative solutions. Consistently, there is a growing shift away from single-marker solutions toward composite biomarker panels guided by multi-omics integration and AI-guided predictive modeling. The chapter will also address current clinical applications of established biomarkers such as HER2 in breast cancer, EGFR in lung cancer, and PD-L1 expression and tumor mutational burden (TMB) in cancer immunotherapy and the limitations these biomarkers have in heterogeneous populations. Further, the ethical and regulatory considerations of biomarker development including data privacy issues in AI-based applications, equitable access to advanced diagnostics in low-resource settings, and cost-effectiveness for roll-out at scale will be addressed. Directions of the future will include developing standardized validation pipelines, interdisciplinarity, and biomarker platforms available globally that can be dynamically calibrated based on patient-specific profiles. Finally, this chapter hopes to set an all-encompassing road map toward closing the gap between the discovery of molecular biomarkers and clinical application in the hope of fashioning a better more accurate, individualized, and equitable future in cancer treatment.